FDA Approves Repotrectinib for Locally Advanced or Metastatic ROS1+ NSCLC
The FDA has approved repotrectinib (Augtyro) for the treatment of adult patients with locally advanced or metastatic ROS1-positive non–small cell lung cancer.
United States Repotrectinib Augtyro Jessicaj Lin Bristol Myers Squibb Drug Administration Harvard Medical School
Source: onclive.com